Literature DB >> 27234378

Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population.

Anna Partyka1, Krzysztof Tupikowski2, Anna Kolodziej2, Romuald Zdrojowy2, Agnieszka Halon3, Bartosz Malkiewicz2, Janusz Dembowski2, Irena Frydecka1, Lidia Karabon4.   

Abstract

OBJECTIVE: T cells play an important role in antitumor immunity, and molecules regulating T-cell activity could influence cancer susceptibility. The distinct role of coinhibitory receptors in immunosurveillance has been considered. B- and T-lymphocyte attenuator (BTLA) is one of these receptors, which negatively regulate immune responses. The aim of this study was to investigate the association between BTLA gene polymorphisms and susceptibility to renal cell carcinoma (RCC) in the Polish population.
METHODS: Altogether 282 patients with RCC and 480 healthy subjects were genotyped for the following polymorphisms: rs2705511, rs1982809, rs9288952, rs16859633, rs9288953, rs2705535, and rs1844089 using the TaqManSNP Genotyping Assays.
RESULTS: Here, we found that the presence of rs1982809G allele (genotype GG+AG) is associated with increased risk of RCC (odds ratio = 1.38; 95% CI: 1.03-1.86; P = 0.03). In patients with clear-cell RCC (ccRCC) with high-grade (3 and 4) tumors, the frequency of rs1982809[GG] genotype was significantly higher as compared to those with low-grade (1 and 2) tumors and to the controls (0.14 vs. 0.06, P = 0.05 and 0.14 vs. 0.06, P = 0.04, respectively). Moreover, we have noticed the trend for overrepresentation of carriers of rs2705511C allele in patients with RCC as compared with the controls (0.51 vs. 0.44, P = 0.08) Haplotype rs2705511C/rs1982809G/rs9288952A/rs9288953T/rs2705535C/rs1844089G (CGATCG) increased the risk of RCC of 46% (odds ratio = 1.46; 95% CI: 1.08-1.96; Pcorrected = 0.05).
CONCLUSION: Our results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BTLA; Coinhibitory molecule; Gene polymorphisms; Renal cancer

Mesh:

Substances:

Year:  2016        PMID: 27234378     DOI: 10.1016/j.urolonc.2016.04.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Rs1982809 is a functional biomarker for the prognosis of severe post-traumatic sepsis and MODs.

Authors:  Lebin Gan; Chen Hu; Zhihong Deng; Hongxiang Lu; Jiali Sun; Guoxuan Peng; Jianxin Jiang; Ling Zeng; Jin Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

2.  CD146 Promoter Polymorphism (rs3923594) Is Associated with Recurrence of Clear Cell Renal Cell Carcinoma in Chinese Population.

Authors:  Gang Feng; Hou-Bao Huang; Xiao-Bing Ye; Peng Zhang; Jian-Jun Huang; Li-Zhu Huang; Long Cheng; Chun Pu; Guorong Li
Journal:  Dis Markers       Date:  2017-05-24       Impact factor: 3.434

3.  Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma.

Authors:  Weifeng Tang; Shuchen Chen; Mingqiang Kang; Jun Liu; Chao Liu
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

Review 4.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

5.  The correlation of BTLA rs1982809 polymorphism with cancer susceptibility: A meta-analysis of 8634 participators.

Authors:  Jian Chen; Jun Wang; Ruihao Liu; Haiwei Xiong; Yingying Liu; Mingzhi Zha; Qiang Li; Xuan Liu; Mingjun Shang; Yingliang Li
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

6.  Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population.

Authors:  Rui Cao; Weifeng Tang; Shuchen Chen
Journal:  J Clin Lab Anal       Date:  2020-02-15       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.